The published trials of tirzepatide have not yet shown definitive cardiovascular outcome benefits, because the trials were designed to look at weight and glucose, not cardiovascular events
GLP-1 receptor agonist is a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, thereby lowering blood sugar
Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients
The advantage of compounded tirzepatide over brand-name for microdosing is flexibility
Findings from a 4-day Alternaria alternata extract intranasal challenge model showed that the absence of GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling exacerbated airway inflammation, characterized by increased lung ILC2s, lymphocytes, eosinophils, and neutrophils, as well as heightened pulmonary expression of type 2 cytokines (IL-5, IL-13), chemokines (CCL11, CCL24), and epithelial ICAM-1